{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-158341","form_type":"8-K","ticker":"ZYME","cik":"0001937653","company_name":"Zymeworks Inc.","filed_at":"2024-06-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.257007+00:00","generated_at":"2026-06-01T05:23:49.114548+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"NMPA accepts zanidatamab BLA in China; Zymeworks earns $8M milestone from BeiGene","bullets":["China's NMPA accepted BLA for zanidatamab in second-line HER2+ biliary tract cancer.","Acceptance triggers $8 million milestone payment from partner BeiGene under Asia Pacific license.","FDA previously granted priority review for same indication; PDUFA target date Nov 29, 2024.","Zanidatamab is also being developed by Jazz Pharmaceuticals in the U.S.","Milestone payment expected to be received following NMPA acceptance."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-158341","json":"https://secwatch.observer/filing/0001193125-24-158341.json","markdown":"https://secwatch.observer/filing/0001193125-24-158341.md","text":"https://secwatch.observer/filing/0001193125-24-158341.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937653/000119312524158341/0001193125-24-158341-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937653/000119312524158341/d761396d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T05:23:49.114548+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}